Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Average Recommendation of “Moderate Buy” by Brokerages

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has been given a consensus recommendation of “Moderate Buy” by the twelve analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $35.75.

A number of equities analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Wednesday, October 8th. Wells Fargo & Company decreased their price objective on Arcturus Therapeutics from $42.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, October 23rd. BTIG Research dropped their target price on Arcturus Therapeutics from $48.00 to $23.00 and set a “buy” rating on the stock in a research report on Wednesday, October 22nd. Guggenheim downgraded Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, October 22nd. Finally, HC Wainwright lowered their price objective on shares of Arcturus Therapeutics from $12.00 to $9.00 and set a “neutral” rating on the stock in a report on Tuesday, November 11th.

Hedge Funds Weigh In On Arcturus Therapeutics

A number of large investors have recently modified their holdings of ARCT. Osaic Holdings Inc. lifted its holdings in Arcturus Therapeutics by 51.8% during the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 738 shares during the last quarter. BNP Paribas Financial Markets increased its position in Arcturus Therapeutics by 163.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after buying an additional 2,586 shares during the period. Strs Ohio acquired a new stake in shares of Arcturus Therapeutics during the first quarter worth $89,000. Compagnie Lombard Odier SCmA bought a new stake in shares of Arcturus Therapeutics in the third quarter valued at about $111,000. Finally, AQR Capital Management LLC bought a new stake in Arcturus Therapeutics in the 1st quarter valued at about $128,000. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Stock Performance

Shares of ARCT opened at $6.78 on Friday. The stock has a 50 day simple moving average of $7.01 and a 200 day simple moving average of $13.03. Arcturus Therapeutics has a 52-week low of $5.85 and a 52-week high of $24.17. The firm has a market capitalization of $192.65 million, a PE ratio of -2.76 and a beta of 2.24.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.60. Arcturus Therapeutics had a negative net margin of 68.35% and a negative return on equity of 28.68%. The firm had revenue of $17.15 million for the quarter, compared to analyst estimates of $17.47 million. Equities research analysts predict that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.